title: Disordered pathways of fibrin turnover in lung lavage of premature infants with respiratory distress syndrome.
abstract: Premature infants who have self-limited respiratory distress syndrome (RDS) rapidly improve, whereas infants with a complicated respiratory course are more likely to develop bronchopulmonary dysplasia (BPD), a chronic lung disorder that is the result of prolonged lung injury and impaired healing. The balance of competing activities of coagulation and fibrinolysis may contribute to the premature lung's response to acute injury and determine, in part, whether there is early resolution or protracted alveolar inflammation. To determine the relative activities of the coagulation and fibrinolytic pathways in neonatal lung injury, procoagulant (PC) and plasminogen activator (PA) activities were measured in undiluted cell-free lung lavage samples obtained serially over the first 28 days of life from 11 infants with self-limited RDS, 11 infants with evolving BPD, and 5 mechanically ventilated control infants without lung disease. Lung lavage from all three groups contained readily detectable procoagulant activity due mainly to the tissue factor-Factor VII complex. Plasminogen activator activity was relatively high in control lavage samples but depressed on the first day of life in the two groups of infants with lung disease: median, 0.3814 IU/ml (control); 0.0541 IU/ml (RDS); and 0.0454 IU/ml (BPD), p < 0.05 in each case compared with control. Two infants with severe lung disease had no detectable plasminogen activator activity in lung lavage on the first day of life. Depressed fibrinolytic activity correlated with severity of lung disease assessed radiographically and by pulmonary function measurements. Plasminogen activator activity was due to both tissue plasminogen activator and urokinase.(ABSTRACT TRUNCATED AT 250 WORDS)
authors: Department of Pediatrics, University of Maryland Hospital, Baltimore 21201.
authors: R M
authors: RM
authors: Viscardi
authors: K
authors: K
authors: Broderick
authors: C C
authors: CC
authors: Sun
authors: A J
authors: AJ
authors: Yale-Loehr
authors: A
authors: A
authors: Hessamfar
authors: V
authors: V
authors: Taciak
authors: K C
authors: KC
authors: Burke
authors: K B
authors: KB
authors: Koenig
authors: S
authors: S
authors: Idell
mesh_terms: D001034:Apgar Score; D015142:Baltimore / Q000453:epidemiology; D001724:Birth Weight; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry*; D001997:Bronchopulmonary Dysplasia / Q000453:epidemiology / Q000209:etiology*; D005069:Evaluation Studies as Topic; D005260:Female; D005337:Fibrin / Q000737:chemistry / Q000378:metabolism*; D005342:Fibrinolysis; D005865:Gestational Age; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007363:Intensive Care Units, Neonatal; D008297:Male; D017395:Plasminogen Activator Inhibitor 1 / Q000737:chemistry; D017396:Plasminogen Activator Inhibitor 2 / Q000737:chemistry; D011237:Predictive Value of Tests; D012127:Respiratory Distress Syndrome, Newborn / Q000150:complications / Q000378:metabolism*; D012307:Risk Factors; D010959:Tissue Plasminogen Activator / Q000737:chemistry; D014568:Urokinase-Type Plasminogen Activator / Q000737:chemistry
chemical_list: D017395:Plasminogen Activator Inhibitor 1; D017396:Plasminogen Activator Inhibitor 2; D005337:Fibrin; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator